Myasthenia Gravis Treatment Klygefa Wins FDA Approval as a Weekly C5 Inhibitor Shot Adults Inject at Home
The FDA approved AstraZeneca's Klygefa (gefurulimab-gaks) for treating adults with acetylcholine receptor antibody-positive generalized myasthenia gravis. The weekly self-injected C5 inhibitor showed improvement in daily-living scores over 26 weeks in a phase 3 trial. AstraZeneca claims it's the first dual-binding nanobody C5 inhibitor, but other C5 inhibitors exist. The drug carries a meningococcal infection risk, requiring vaccination before use.
How this was made

The 30-second read
Why it matters
The approval adds a differentiated therapy to AZN's pipeline, potentially expanding market share in the niche autoimmune space.
Market read
New FDA approval could drive short‑term stock movement and longer‑term revenue growth for AstraZeneca.
What to watch
Potential competition from existing IV C5 inhibitors and the need for mandatory meningococcal vaccination.
Background
AstraZeneca's Rare Disease unit received FDA clearance for Klygefa, a weekly self‑injectable nanobody targeting complement protein C5, addressing unmet needs in antibody‑positive myasthenia gravis.
Ticker impact
FDA approved AstraZeneca's Klygefa (gefurulimab-gaks) for adult generalized myasthenia gravis.
potential upside as investors price in new revenue stream from a high‑cost specialty drug.
Approval creates a novel product line; market impact will depend on pricing and uptake, but the news is material.
Market effects
May lift other rare‑disease and C5‑inhibitor biotech stocks.
US biotech sector could see modest gains.
Sets a precedent for weekly nanobody C5 inhibitors worldwide.
Counterpoint
If pricing is high and reimbursement uncertain, the drug could weigh on AZN.
Key entities
- CompanyAstraZeneca
Pharmaceutical company receiving FDA approval for Klygefa.

